


 












Gil M. Labrucherie, Nektar Therapeutics CFO & SVP - REDBOOKS








































Brands, Marketers, Agencies. Search Less. Sell More.





/   SIGN IN

GET A FREE TRIAL   
CONTACT US: (800) 908-5395





















Gil M. Labrucherie
CFO & SVP, Nektar Therapeutics

EMAIL: 
                      







              Real-time sales trigger feed - generated by REDBOOKS machine learning and natural language processing technology, tracking 800,000+ news sources to aggregate all new executives, job/role changes and news on decision makers, brands and agencies in the media/marketing industry.
              

              This sales feed is for Gil M. Labrucherie at Nektar Therapeutics. Gil M. Labrucherie works as CFO & SVP , acting in a Executive Management role .  Nektar Therapeutics is a leader in Pharmaceuticals & Health Care Products .
              REDBOOKS tracks personnel changes for advertisers spending over $1 million annually.
              

              For more Executive Management leads or media/marketing prospecting automation, start a free trial now.
              

Recent Related News


07/13/2017:


Nektar Therapeutics (NASDAQ:NKTR) Closed 7.8% Above Its 50 Day Average

Shares last traded at $20.85 which is slightly above $19.35, the stock’s 50 day moving average and marginally over the 200 day moving average of $16.66. The 50 day moving average was up $1.50 and the 200 day average went up by +25.19%. Trading volume for Nektar Therapeutics was 843K on Thursday. Overall, volume was down 45.03% under the stocks normal daily volume.
Traders are feeling more bearish on shares of the company if you look at the motion in short interest. The company realized a rise in short interest of 6.27% between June 15, 2017 and May 31, 2017. .....

People In This Article:
Gil M. Labrucherie
,                                            Howard W. Robin
 

06/30/2017:


Nektar Therapeutics (NASDAQ:NKTR) Short Interest Up 6.27% – Currently Trading Up

Traders are feeling more bearish on Nektar Therapeutics lately looking at the uptick in short interest. The firm experienced a rise in short interest between June 15, 2017 and May 31, 2017 of 6.27%. Short shares increased 657,635 over that timeframe. The short-interest ratio increased to 8.4 and the short interest percentage is 0.07% as of May 31.
Here is the rundown on market activity for Nektar Therapeutics (NASDAQ:NKTR). Sr VP John Nicholson sold 101,700 shares at an average price of $19.24 on Wed the 7th. .....

People In This Article:
Gil M. Labrucherie
,                                            Howard W. Robin
,                                            John Nicholson
 






Learn more about Gil M. Labrucherie  and 260,000+ key contacts

  Create targeted lead lists

  Gain insider knowledge with advanced machine  learning
  Real-time verified contact info



Enter Work Email:

Please enter email address.
 Please enter valid email address.









             Learn more about Gil M. Labrucherie and 260,000+ key contacts
            



























First Name *

 Please enter first name.




Last Name *

 Please enter last name.






Company Name *

 Please enter company name.






Email *





Phone *

 Please enter phone number.
 Please enter 10 digits number.





What industry are you in? *  
                (Please select one the categories below)
Please enter value for the industry.




                     Media Sales
                  




                     Production
                  




                     Ad-Tech/Mar-Tech
                  




                     Sponsorship Sales
                  



  Agency New Business
                  



  Other:
                  




What is your role? *
                 
                 (Please select one the categories below)
Please enter value for the role.



  C-Suite
                  



  VP/Manager
                  



  Sales Rep
                  



  Other:
                  














Thank you for registering for a Free REDBOOKS.com Trial!
We are processing your request and will be in touch shortly to get you started!
For Immediate Assistance, please call us at (800) 908-5395 or email us at info@redbooks.com


























Home
Learn More
FREE Trial


Features




AD THINK Events
Thought Leadership Events
Top Advertiser Directory
Top Agency Directory



Add Your Agency
Update Your Agency
Agency Showcase
Advertising Associations
Creative Spotlight
Services and Suppliers


About Us
Blog
Contact Us
Jobs
Terms & Conditions
Privacy Policy





Customer Support
(800) 908-5395
Connect with us




















Copyright © 2017 Red Books LLC. All rights reserved









































Gil M. Labrucherie Jr. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In




















Gil M. Labrucherie Jr.
Senior Vice President and Chief Financial Officer at Nektar Therapeutics


View Full Profile
Are you Gil M. Labrucherie Jr.? Claim your profile


 


Sign up for Equilar Atlas and view Gil M. Labrucherie Jr.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Gil M. Labrucherie Jr.'s  network and community.
												FOLLOW changes in Gil M. Labrucherie Jr.'s employment and money-in-motion.
												CONNECT with Gil M. Labrucherie Jr. through your network of contacts.
												








Gil M. Labrucherie Jr.'s Executive Work History


Current


Senior Vice President and Chief Financial Officer, 
Nektar Therapeutics


Past
To view Gil M. Labrucherie Jr.'s complete executive work history, sign up now
Education


														 B.A., 
															University of California - Davis


														 J.D., 
															University of California - Berkeley


Age
45

 
 


Gil M. Labrucherie Jr.'s Biography



Gil M. Labrucherie has served as our Senior Vice President and Chief Financial Officer since June 2016. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible for global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Cor ...
(Read More)

			Gil M. Labrucherie has served as our Senior Vice President and Chief Financial Officer since June 2016. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible for global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Labrucherie received his J.D. from the Berkeley Law School and a B.A. from the University of California Davis.
		
Source: Nektar Therapeutics on 03/01/2017
		
	

 






Sign up for Equilar Atlas and view Gil M. Labrucherie Jr.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Gil M. Labrucherie Jr.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Gil M. Labrucherie Jr.'s  network and community.
												FOLLOW changes in Gil M. Labrucherie Jr.'s employment and money-in-motion.
												CONNECT with Gil M. Labrucherie Jr. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Gil M. Labrucherie Jr.


















Gil M. Labrucherie Jr.'s Connections (23)





Sign up now to view Gil M. Labrucherie Jr.'s 23 connections »









Michael A. Brown
Former Chief Executive Officer and Director, Symantec Corporation









Maninder Hora
Senior Vice President, Pharmaceutical Development and Manufacturing Operations, Nektar Therapeutics









Dennis L. Winger
Board Member, Accuray Incorporated









Roy A. Whitfield
Board Member, Nektar Therapeutics









Ivan P. Gergel
Senior Vice President, Drug Development and Chief Medical Officer, Nektar Therapeutics









David Johnston
Former SVP, Research & Development, Nektar Therapeutics









Robert B. Chess
Chairman of the Board, Nektar Therapeutics









Lutz Lingnau
Board Member, Nektar Therapeutics









John S. Patton
Former Chief Scientific Officer, Nektar Therapeutics









Irwin Lerner
Former Chair.,Interim Pres.,CEO, Medarex








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









Claiborne P. Deming
Chairman of the Board, Murphy Oil Corporation









Daniel A. DeMatteo
Executive Chairman, GameStop Corp.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993






















Gil M. Labrucherie Jr. - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In




















Gil M. Labrucherie Jr.
Senior Vice President and Chief Financial Officer at Nektar Therapeutics


View Full Profile
Are you Gil M. Labrucherie Jr.? Claim your profile


 


Sign up for Equilar Atlas and view Gil M. Labrucherie Jr.'s full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Gil M. Labrucherie Jr.'s  network and community.
												FOLLOW changes in Gil M. Labrucherie Jr.'s employment and money-in-motion.
												CONNECT with Gil M. Labrucherie Jr. through your network of contacts.
												








Gil M. Labrucherie Jr.'s Executive Work History


Current


Senior Vice President and Chief Financial Officer, 
Nektar Therapeutics


Past
To view Gil M. Labrucherie Jr.'s complete executive work history, sign up now
Education


														 B.A., 
															University of California - Davis


														 J.D., 
															University of California - Berkeley


Age
45

 
 


Gil M. Labrucherie Jr.'s Biography



Gil M. Labrucherie has served as our Senior Vice President and Chief Financial Officer since June 2016. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible for global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Cor ...
(Read More)

			Gil M. Labrucherie has served as our Senior Vice President and Chief Financial Officer since June 2016. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible for global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Labrucherie received his J.D. from the Berkeley Law School and a B.A. from the University of California Davis.
		
Source: Nektar Therapeutics on 03/01/2017
		
	

 






Sign up for Equilar Atlas and view Gil M. Labrucherie Jr.'s full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Gil M. Labrucherie Jr.. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Gil M. Labrucherie Jr.'s  network and community.
												FOLLOW changes in Gil M. Labrucherie Jr.'s employment and money-in-motion.
												CONNECT with Gil M. Labrucherie Jr. through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Gil M. Labrucherie Jr.


















Gil M. Labrucherie Jr.'s Connections (23)





Sign up now to view Gil M. Labrucherie Jr.'s 23 connections »









Michael A. Brown
Former Chief Executive Officer and Director, Symantec Corporation









Maninder Hora
Senior Vice President, Pharmaceutical Development and Manufacturing Operations, Nektar Therapeutics









Dennis L. Winger
Board Member, Accuray Incorporated









Roy A. Whitfield
Board Member, Nektar Therapeutics









Ivan P. Gergel
Senior Vice President, Drug Development and Chief Medical Officer, Nektar Therapeutics









David Johnston
Former SVP, Research & Development, Nektar Therapeutics









Robert B. Chess
Chairman of the Board, Nektar Therapeutics









Lutz Lingnau
Board Member, Nektar Therapeutics









John S. Patton
Former Chief Scientific Officer, Nektar Therapeutics









Irwin Lerner
Former Chair.,Interim Pres.,CEO, Medarex








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









Claiborne P. Deming
Chairman of the Board, Murphy Oil Corporation









Daniel A. DeMatteo
Executive Chairman, GameStop Corp.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993













    Gil Labrucherie | Nektar Therapeutics | ZoomInfo.com










 




Gil Labrucherie |  | Decypha

































Sign In
|
Welcome  Guest 









 







Regions

GCC
                                |
                                    Levant
                                |
                                    MENA
                                |
                                    North Africa




GCC

Bahrain
                            |
                            Kuwait
                            |
                            Oman
                            |
                            Qatar
                            |
                            Saudi Arabia
                            |
                            United Arab Emirates




Levant

Iraq
                            |
                            Jordan
                            |
                            Lebanon
                            |
                            Palestine




North Africa

Egypt
                            |
                            Libya
                            |
                            Morocco
                            |
                            Tunisia




Others

Iran
                            |
                            Turkey
                            |
                            United Kingdom
                            |
                            United States












Advanced Search















News






Markets






Companies






Research






Funds






Fixed Income






Money Markets






Commodities






FX






Economics






Analysis






More











Sign In
Membership
Customize Your Decypha
Logout
Welcome
Decypha Alerts












Home




People Profiles




People Profile



Gil Labrucherie Profile














Full Name:

                                                    Gil Labrucherie
                                                







Country:











Biography


                                                    Gil M. Labrucherie has served as our Senior Vice President, General Counsel and Secretary since April 2007, responsible for all aspects of our legal affairs.... 











Designations




Date
Designation
Entity
Entity Description
Country




2005


Nektar Therapeutics, Inc.

Pharmaceuticals, Biotechnology & Life Sciences

                                                United States










Check all the  individuals in 
Check The List






Request a Trial
















Title:*


Select
Mr
Mrs
Ms
Miss
Dr
Prof




First Name:*



Last Name:*



Job Title:*


Select
 Asset Managers
 Corporate Banks
 Investment Managers
 Wealth Managers
 Consultants & Advisors
 Legal Practioners
 Academics
 Hedge Funds
 Private Equity Analysts
 Traders
 Equity Research Analysts




Phone:*



Company:*




Email:*




Country:*


Select

                                                Afganistan
                                        

                                                Albania
                                        

                                                Algeria
                                        

                                                American Samoa
                                        

                                                Andorra
                                        

                                                Angola
                                        

                                                Anguilla
                                        

                                                Antarctica
                                        

                                                Antigua and Barbuda
                                        

                                                Argentina
                                        

                                                Armenia
                                        

                                                Aruba
                                        

                                                Australia
                                        

                                                Austria
                                        

                                                Azerbaijan
                                        

                                                Bahamas
                                        

                                                Bahrain
                                        

                                                Bangladesh
                                        

                                                Barbados
                                        

                                                Belarus
                                        

                                                Belgium
                                        

                                                Belize
                                        

                                                Benin
                                        

                                                Bermuda
                                        

                                                Bhutan
                                        

                                                Bolivia
                                        

                                                Bosnia and Herzegovina
                                        

                                                Botswana
                                        

                                                Bouvet Island
                                        

                                                Brazil
                                        

                                                British Indian Ocean Territory
                                        

                                                Brunei
                                        

                                                Bulgaria
                                        

                                                Burkina Faso
                                        

                                                Burundi
                                        

                                                Cambodia
                                        

                                                Cameroon
                                        

                                                Canada
                                        

                                                Cape Verde
                                        

                                                Cayman Islands
                                        

                                                Central African Republic
                                        

                                                Chad
                                        

                                                Chile
                                        

                                                China
                                        

                                                Christmas Island
                                        

                                                Cocos (Keeling) Islands
                                        

                                                Colombia
                                        

                                                Comoros
                                        

                                                Congo
                                        

                                                Cook Islands
                                        

                                                Costa Rica
                                        

                                                Cote D'Ivoire (Ivory Coast)
                                        

                                                Croatia (Hrvatska)
                                        

                                                Cuba
                                        

                                                Curacao
                                        

                                                Cyprus
                                        

                                                Czech Republic
                                        

                                                Czechoslovakia (former)
                                        

                                                Denmark
                                        

                                                Djibouti
                                        

                                                Dominica
                                        

                                                Dominican Republic
                                        

                                                East Timor
                                        

                                                Ecuador
                                        

                                                Egypt
                                        

                                                El Salvador
                                        

                                                Equatorial Guinea
                                        

                                                Eritrea
                                        

                                                Estonia
                                        

                                                Ethiopia
                                        

                                                Falkland Islands (Malvinas)
                                        

                                                Faroe Islands
                                        

                                                Fiji
                                        

                                                Finland
                                        

                                                France
                                        

                                                France, Metropolitan
                                        

                                                French Guiana
                                        

                                                French Polynesia
                                        

                                                French Southern Territories
                                        

                                                Gabon
                                        

                                                Gambia
                                        

                                                Georgia
                                        

                                                Germany
                                        

                                                Ghana
                                        

                                                Gibraltar
                                        

                                                Greece
                                        

                                                Greenland
                                        

                                                Grenada
                                        

                                                Guadeloupe
                                        

                                                Guam
                                        

                                                Guatemala
                                        

                                                Guernsey
                                        

                                                Guinea
                                        

                                                Guinea-Bissau
                                        

                                                Guyana
                                        

                                                Haiti
                                        

                                                Heard and McDonald Islands
                                        

                                                Honduras
                                        

                                                Hong Kong
                                        

                                                Hungary
                                        

                                                Iceland
                                        

                                                India
                                        

                                                Indonesia
                                        

                                                Iran
                                        

                                                Iraq
                                        

                                                Ireland
                                        

                                                Isle of Man
                                        

                                                Israel
                                        

                                                Italy
                                        

                                                Jamaica
                                        

                                                Japan
                                        

                                                Jersey
                                        

                                                Jordan
                                        

                                                Kazakhstan
                                        

                                                Kenya
                                        

                                                Kiribati
                                        

                                                Kuwait
                                        

                                                Kyrgyzstan
                                        

                                                Laos
                                        

                                                Latvia
                                        

                                                Lebanon
                                        

                                                Lesotho
                                        

                                                Liberia
                                        

                                                Libya
                                        

                                                Liechtenstein
                                        

                                                Lithuania
                                        

                                                Luxembourg
                                        

                                                Macau
                                        

                                                Macedonia
                                        

                                                Madagascar
                                        

                                                Malawi
                                        

                                                Malaysia
                                        

                                                Maldives
                                        

                                                Mali
                                        

                                                Malta
                                        

                                                Marshall Islands
                                        

                                                Martinique
                                        

                                                Mauritania
                                        

                                                Mauritius
                                        

                                                Mayotte
                                        

                                                Mexico
                                        

                                                Micronesia
                                        

                                                Moldova
                                        

                                                Monaco
                                        

                                                Mongolia
                                        

                                                Montenegro
                                        

                                                Montserrat
                                        

                                                Morocco
                                        

                                                Mozambique
                                        

                                                Myanmar
                                        

                                                Namibia
                                        

                                                Nauru
                                        

                                                Nepal
                                        

                                                Netherlands
                                        

                                                Netherlands Antilles
                                        

                                                Neutral Zone
                                        

                                                New Caledonia
                                        

                                                New Zealand (Aotearoa)
                                        

                                                Nicaragua
                                        

                                                Niger
                                        

                                                Nigeria
                                        

                                                Niue
                                        

                                                Norfolk Island
                                        

                                                North Korea
                                        

                                                Northern Mariana Islands
                                        

                                                Norway
                                        

                                                Oman
                                        

                                                Pakistan
                                        

                                                Palau
                                        

                                                Palestine
                                        

                                                Panama
                                        

                                                Papua New Guinea
                                        

                                                Paraguay
                                        

                                                Peru
                                        

                                                Philippines
                                        

                                                Pitcairn
                                        

                                                Poland
                                        

                                                Portugal
                                        

                                                Puerto Rico
                                        

                                                Qatar
                                        

                                                Reunion
                                        

                                                Romania
                                        

                                                Russia
                                        

                                                Rwanda
                                        

                                                S. Georgia and S. Sandwich Isls.
                                        

                                                Saint Kitts and Nevis
                                        

                                                Saint Lucia
                                        

                                                Saint Vincent and the Grenadines
                                        

                                                Samoa
                                        

                                                San Marino
                                        

                                                Sao Tome and Principe
                                        

                                                Saudi Arabia
                                        

                                                Senegal
                                        

                                                Serbia
                                        

                                                Seychelles
                                        

                                                Sierra Leone
                                        

                                                Singapore
                                        

                                                Slovak Republic
                                        

                                                Slovenia
                                        

                                                Solomon Islands
                                        

                                                Somalia
                                        

                                                South Africa
                                        

                                                South Korea
                                        

                                                South Sudan
                                        

                                                Spain
                                        

                                                Sri Lanka
                                        

                                                St. Helena
                                        

                                                St. Pierre and Miquelon
                                        

                                                Sudan
                                        

                                                Suriname
                                        

                                                Svalbard and Jan Mayen Islands
                                        

                                                Swaziland
                                        

                                                Sweden
                                        

                                                Switzerland
                                        

                                                Syria
                                        

                                                Taiwan
                                        

                                                Tajikistan
                                        

                                                Tanzania
                                        

                                                Thailand
                                        

                                                Togo
                                        

                                                Tokelau
                                        

                                                Tonga
                                        

                                                Trinidad and Tobago
                                        

                                                Tunisia
                                        

                                                Turkey
                                        

                                                Turkmenistan
                                        

                                                Turks and Caicos Islands
                                        

                                                Tuvalu
                                        

                                                US Minor Outlying Islands
                                        

                                                USSR (former)
                                        

                                                Uganda
                                        

                                                Ukraine
                                        

                                                United Arab Emirates
                                        

                                                United Kingdom
                                        

                                                United States
                                        

                                                Uruguay
                                        

                                                Uzbekistan
                                        

                                                Vanuatu
                                        

                                                Vatican City State (Holy See)
                                        

                                                Venezuela
                                        

                                                Vietnam
                                        

                                                Virgin Islands (British)
                                        

                                                Virgin Islands (U.S.)
                                        

                                                Wallis and Futuna Islands
                                        

                                                Western Sahara
                                        

                                                Yemen
                                        

                                                Yugoslavia
                                        

                                                Zaire
                                        

                                                Zambia
                                        

                                                Zimbabwe
                                        




Comments:





*Required Fields


 

 Submit








Already Registered?








Login attempt was not successful. Please try again








Username/ Email:



Password:





Enter Characters:















 

 Login





 Forget your password?
























By Job Title


Asset Managers |
                                    Corporate Banks |
                                    Investment Managers |
                                    Wealth Managers |
                                    Consultants & Advisors |
                                    Legal Practitioners |
                                    Academics |
                                    Hedge Funds |
                                    Private Equity Analysts |
                                    Traders |
                                    Equity Research Analysts


By Scope


Equity |
                                    Fixed Income |
                                    Funds |
                                    Excel  |
                                    Analytical Tools  |
                                    Markets  |
                                    Prices  |
                                    Money Market |
                                    News |
                                    Industry |
                                    IPOs |
                                    Mergers & Acquisitions |
                                    Commodities |
                                    Economics



Covered Countries and Exchanges

















Add Your Company | 
                                        Add Yourself | 
                                        Terms and Conditions | 
                                        Privacy Policy | 
                                        About DirectFN









Copyright ©  DirectFN. All Rights Reserved.











Data Not Available









Login











Login attempt was not successful. Please try again


Username/ Email:


Password:



Enter Characters:











 Forget your password?











Back to Top

Support & Feedback


Ask for free trial









Request a Trial
















Title:*


Mr
Mrs
Ms
Miss
Dr
Prof




First Name:*



Last Name:*



Email:*




Phone:*



Promo. Code:



Country:*


Select
Afganistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Cote D'Ivoire (Ivory Coast)
Croatia (Hrvatska)
Cuba
Curacao
Cyprus
Czech Republic
Czechoslovakia (former)
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
France, Metropolitan
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard and McDonald Islands
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
Neutral Zone
New Caledonia
New Zealand (Aotearoa)
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
S. Georgia and S. Sandwich Isls.
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovak Republic
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
South Sudan
Spain
Sri Lanka
St. Helena
St. Pierre and Miquelon
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
US Minor Outlying Islands
USSR (former)
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City State (Holy See)
Venezuela
Vietnam
Virgin Islands (British)
Virgin Islands (U.S.)
Wallis and Futuna Islands
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




Company:*



Job Title:


Select
 Academics
 Asset Managers
 Consultants & Advisors
 Corporate Banks
 Equity Research Analysts
 Hedge Funds
 Investment Managers
 Legal Practioners
 Private Equity Analysts
 Traders
 Wealth Managers




Comments:




*Required Fields


 

 Submit



















Contact Us












Hello ,Please use the below form for
                            Product support & feedback


Name :  *  


Email:  * 


Phone Number :  * 






Preferred contact method :
Email
Phone











Technical Support 24x7: +94 112 314900 / slhops@directfn.net
Your Account Manager is, , , 






















 Get a Decypha Membership to view this content..................







Get a Decypha Membership


 Get the membership of Decypha Premium Package to access more exciting features including advanced analytical tools and the Pro 10 package. Pro 10 is designed keeping active investors in mind and offers a flexible framework to view information and do analysis the way you desire.

All you need to access these valuable features is to click on the Get a membership button and submit your details to our sales team.















Upgrade your Membership


 Account is not entitled to view this information.

 Please contact your account manager to upgrade your Membership.

Email :  support@decypha.com






 Register to view this content..................







 Decypha Free Registration


Register free with Decypha and get access to real-time price information and many other features including Technical Scanner, Fundamental Screener etc.

Just click the Registration button, submit your details and get registered for free.








 





Labrucherie Gil M - SEC Form 4 Insider Trading Screener - OpenInsider











OpenInsider

Latest

Latest Cluster Buys
Latest Insider Trading (all filings)
Latest Insider Purchases
Latest Insider Purchases $25k+
Latest Officer Purchases $25k+
Latest CEO/CFO Purchases $25k+
Latest Insider Sales
Latest Insider Sales $100k+
Latest Officer Sales $100k+
Latest CEO/CFO Sales $100k+


Top

Top Officer Purchases Today
Top Officer Purchases Past Week
Top Officer Purchases Past Month
Top Insider Purchases Today
Top Insider Purchases Past Week
Top Insider Purchases Past Month
Top Insider Sales Today
Top Insider Sales Past Week
Top Insider Sales Past Month


By Symbol

Officer Purchases $25k+ Today
Officer Purchases $25k+ Past Week
Officer Purchases $25k+ Past Month
Officer Sales $100k+ Today
Officer Sales $200k+ Past Week
Officer Sales $500k+ Past Month
Officer Sales $100k+ Today (no opt-ex)
Officer Sales $200k+ Past Week (no opt-ex)
Officer Sales $500k+ Past Month (no opt-ex)
Insider Purchases of Penny Stocks, Past Month
Insider Sales of Penny Stocks, Past Month


Charts

Contact











Labrucherie Gil M - SEC Form 4 Insider Trading ScreenerCIK: 1394875 - Address: C/o Nektar Therapeutics, 455 Mission Bay Boulevard South, San Francisco, CA 94158 




General

Tickers
Insider
Sh Price $



Lqdty M$






Date

Filing Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  



Trade Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  


Filing Delay



N Days Ago








Transaction Filing

 P - Purchase S - Sale A - Grant D - Sale to Iss G - Gift F - Tax M - Option Ex X - Option Ex C - Cnv Deriv W - Inherited

 No deriv


 Multiple Days

Traded K$



Own Chg %








Industry




All Sectors (except Funds)
Agriculture, Forestry, Fish
Mining
Construction
Manufacturing
Transportation & Utilities
Wholesale Trade
Retail Trade
Financial
Services
Closed-End Funds


























Insider Title

  Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other






Group by


Filing
Company





Company Totals

Num Filings



Num Insiders



Num Officers



Traded K$



Own Chg %







Sort by

Filing Date
Trade Date
Ticker Symbol
Trade Value


Max Results
Page


clear


Real-time CSV, Options, Alerts








14 results -  -  -  -  -  -  - TCcnt1d1w1m6mS13-0+0+14+15 


X
Filing Date
Trade Date
Ticker
Insider NameInsider Title
Trade Type 
Share Price
Shares Traded
Shares Owned
Own chg
Value Traded
1d ret
1w ret
1m ret
6m ret



2017-05-18 20:48:232017-05-16 NKTRLabrucherie Gil MSVP, CFOS - Sale$19.55-3,17966,091-5%-$62,149
DM2017-03-03 19:04:552017-03-02 NKTRLabrucherie Gil MSVP, CFOS - Sale+OE$15.16-200,00069,270-74%-$3,031,950-2+5+60
2017-02-17 20:04:542017-02-16 NKTRLabrucherie Gil MSVP, CFOS - Sale$13.14-2,35969,270-3%-$30,997+2+3+69
2016-11-18 18:10:372016-11-16 NKTRLabrucherie Gil MSVP, CFOS - Sale$13.96-1,65451,129-3%-$23,090-3-3-7
2016-08-17 17:39:402016-08-16 NKTRLabrucherie Gil MSVP, CFOS - Sale$17.56-3,30552,783-6%-$58,0360+3+9-23
D2016-05-18 17:12:342016-05-17 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$13.58-8367,921-10%-$11,353-2+7+10+6
D2016-02-18 19:45:542016-02-17 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$11.92-8276,590-11%-$9,858+10+8+52
D2016-02-12 17:20:202016-02-10 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$11.49-11,6665,251-69%-$134,0420-1+13+50
D2016-01-21 18:02:582016-01-19 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$14.12-11,6675,251-69%-$164,738+3+1-20+7
D2015-12-07 17:36:262015-12-03 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$15.87-45,0015,251-90%-$714,16600+2+4
D2015-11-13 17:35:292015-11-11 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$13.52-45,0004,751-90%-$608,400+2+12+14+4
D2015-10-08 19:11:092015-10-06 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$10.99-45,0004,751-90%-$494,550+5-7+14+42
D2015-09-25 17:22:042015-09-23 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$13.04-44,9994,751-90%-$586,787-6-10-5+5
D2015-08-17 16:04:262015-08-13 NKTRLabrucherie Gil MSVP, GCS - Sale+OE$10.89-33,3334,751-88%-$362,996-3-10+12+1
Real-time CSV? Options? Alerts? Contact us!



AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price


S - SaleSale of securities on an exchange or to another personS - Sale+OESale of securities on an exchange or to another person (after option exercise)F - TaxPayment of exercise price or tax liability using portion of securities received from the companyP - PurchasePurchase of securities on an exchange or from another person 

Return to top
Copyright © 2017 openinsider.com. All rights reserved.














Gil and Sandra Labrucherie                                                                                               - Santa Rosa                                        , CA         - Company Information









 



























Products
Resources
My Account












Talk to a D&B Advisor 
1-800-280-0780 




Business Directory



CA



Santa Rosa



Animal Specialty Services



Boarding Services, Horses: Racing And Non-racing



                            Gil and Sandra Labrucherie
                                    



 





















G 


Gil and Sandra Labrucherie                                                                                              
CLAIM THIS BUSINESS



5915 FAUGHT RD SANTA ROSA, CA 95403
Get Directions



(707) 836-0799
www.fieldstonefarm.biz                                                                                  





Business Info



 Founded 1996
 Incorporated 
 Annual Revenue $72,800.00
 Employee Count 1
 Industries Boarding Services, Horses: Racing And Non-racing
 Contacts Gil Labrucherie                                                                                                         







Contact Business







Your Email Address

Subject:


Message


Send Message





Company Summary


Since 1996, Gil And Sandra Labrucherie                                                                                               has been providing Boarding Services, Horses: Racing And Non-racing from Santa Rosa. 









VERIFIED Status:
UNVERIFIED



Address:
UNVERIFIED





LAST VERIFIED:

                                    --
                                



Phone:

                                    UNVERIFIED
                                





Payment Method:
UNVERIFIED


view full report





Similar Businesses Nearby


                                        Our similar businesses nearby shows similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Competitive Landscape


                                        Our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Payments Accepted

NO DATA



Hours



                                        Sunday 

                                        

                                                                                            --
                                            
                                        



                                        Monday 

                                        

                                                                                            --
                                            
                                        



                                        Tuesday 

                                        

                                                                                            --
                                            
                                        



                                        Wednesday 

                                        

                                                                                            --
                                            
                                        



                                        Thursday 

                                        

                                                                                            --
                                            
                                        



                                        Friday 

                                        

                                                                                            --
                                            
                                        



                                        Saturday 

                                        

                                                                                            --
                                            
                                        







G

VIEW ADDITIONAL DATA                        
Select from over 115 networks below to view available data about this business. If this data is unavailable or inaccurate and you own or represent this business, click here for more information on how you may be able to correct it. 







Credibility Review





Google





Facebook.com





Yellowbook.com





Bing.com





Yellowpages.com





MerchantCircle





Tele Atlas (TomTom)





Twitter.com





AOL





MapQuest





Yahoo Local





Apple/Siri





Groupon





Hotfrog.com





Comcast.net Search





ReachLocal





Admedia





Dealsplus





Shoptopia.com





Alteryx





Dogtime Media





KSL.com





Sirtune





AmericanTowns.com





Driverside





Kudzu.com





SpecialsAgent.com





Answers.com





eGood





LawInfo.com





spotlikes.com





anywho.com





eGumball





Likeness.com





Spotzot





eServiceLog





MapMyRun





TechnoCom





apartmentguide.com





ezlocal.com





EZToUse.com





Teleroute





AroundMe.com





metropolist.com





Therapists.com





Atlanta NewHomes





FindLaw.com





Time Out New York





Avantar





FindTheBest.com





mojopages.com





B2B Yellowpages





Fivestar Software





MyCityWay.com





TripAdvisor





bckyrd.com





GiftCards.com





MyCoupons.com





beachcalifornia.com





GoLocal247.com





mymove.com





UpMeSocial.com





Belo





GoodInfo





News-Gazette





Nokia





usdirectory.com





Cars.com





Nomao





Centzy.com





hibu





Openlist.com





ChaCha Search





Homeplate.com





OwnLocal.com





VisiKard





challama.com





Homestore





patch.com





Voltari





CityBot





Pelopidas





Vouchd





ClassifiedAds





Hostway





PlaceIQ





WalkScore.com





CloudMade





Hoodoyou





PlanetDiscover.com





WeddingWire.com





PowerProfiles





Where Inc.





Contractors.com





iGoLocal.com





Radiate Media





Wikiocity





CouponMap





Indeed.com





Wimgo.com





CrowdSpot





Innova Electronics





Intellistrand





realtor.com





DataSphere





InTheMO.com





Reply.com





Yellowbot.com





JiWire





Rocket Fuel





YellowPageCity.com





DMV.org





Justclicklocal.com





Dirxion





Keen.com





Zidster.com












Photos














































Business Credit Report
Receive a one-time comprehensive credit report on this company.
get full credit report


Facebook








Twitter








Yelp






































Call 1.800.280.0780 to speak with a D&B Advisor Today!







Customer Resources
Products
Education Center
Business Articles & Insights
Glossary
Contact Us
Customer Support
Communication Preferences
Search for D&B D-U-N-S




Our Company
About Us
Company History
Business Credit History
Careers
Press Releases
News
Success Stories
Hoovers




Our Network
Partners
Affiliates
Blog
Access to Capital
Entrepreneurial Initiative
D&B International
SupplierEdge




Site Links
Business Directory
Site Map
PIPEDA
Privacy Policy
Website Terms of Service
Product License Agreement







© Dun & Bradstreet, Inc. 2017. All rights reserved.






















Nektar | Company | Our Leadership



























































Our Leadership Our
leadership, including the management team and Board of Directors, is made up of
biotechnology and pharmaceutical industry experts who are recognized for their
contributions in the discovery and development of new therapies and their
success in bringing new treatments to patients and physicians.







          Howard W. Robin        

            President and Chief Executive Officer          




Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion.

Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co.

Mr. Robin serves as a director of the Biotechnology Industry Organization, the world's largest biotechnology industry trade organization, and also serves as a director of BayBio, a non-profit trade association serving the Northern California life sciences community.

Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey and serves as a member of its Board of Trustees.
 Close Bio










          Stephen K. Doberstein, Ph.D.        

            Senior Vice President and Chief Scientific Officer          




Steve Doberstein joined Nektar in January 2010 as Senior Vice President and Chief Scientific Officer to lead all aspects of discovery research at Nektar. Dr. Doberstein brings over 17 years of experience in biotechnology research and development to the company. Prior to joining Nektar, Dr. Doberstein was Vice President of Research at XOMA where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/ pharmacodynamics. Prior to that, Dr. Doberstein served as Vice President, Research at Five Prime Therapeutics, Inc, a protein and antibody discovery and development company where he built and led a high performance discovery research and process development group. While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. Prior to that, Dr. Doberstein was Vice President, Research at Xencor, an antibody and protein engineering and development company. At Xencor, he was instrumental in advancing its protein platform technologies and preclinical product candidates. Before that, he also held a number of senior positions at Exelixis.Dr. Doberstein received his Ph.D. in Biochemistry, Cell and Molecular Biology from the Johns Hopkins University School of Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Doberstein held a variety of engineering roles at DuPont after receiving his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware. Close Bio










          Ivan Gergel, M.D.        

            Senior Vice President, Drug Development and Chief Medical Officer          




Ivan Gergel joined Nektar in May 2014 as Senior Vice President, Drug Development & Chief Medical Officer to oversee the company's clinical strategy and activities, including direct supervision of clinical research, medical affairs, regulatory affairs and drug safety and surveillance. Dr. Gergel brings over 25 years of pharmaceutical leadership and drug development experience to Nektar with deep expertise in all aspects of the clinical and regulatory process.

Prior to joining Nektar, Dr. Gergel served as Executive Vice President, Research & Development of Endo Pharmaceuticals and Chief Scientific Officer, where he led clinical, research, regulatory, project management and medical affairs. During his tenure with Endo, Dr. Gergel was responsible for a number of late stage development programs and product approvals, including BEMA® Buprenorphine, which is in Phase 3, Abuse-Deterrent Opana® ER for chronic pain, and Fortesta® and Aveed™ for hypogonadism. Prior to joining Endo, Dr. Gergel served as Senior Vice President of Research and Development for Forest Laboratories Inc. As the head of the clinical organization and then as the senior R&D executive for the company, Dr. Gergel oversaw the successful development programs leading to the approval of numerous NCEs to treat a range of CNS disorders and other medical conditions, including Celexa® for depression, Aerospan™ for asthma, Lexapro® for depression and generalized anxiety disorder, Namenda® for Alzheimer's Disease, Combunox™ for acute pain and Savella® for fibromyalgia. Dr. Gergel also led the organization through the approval and launch of Bystolic® for hypertension and Campral® for alcohol dependency. In addition, while at Forest Laboratories Inc. Dr. Gergel led the R&D team responsible for the successful in-licensing or acquisition of several new agents including Turdoza™ for COPD, Linzess® for IBS, and the anti-infective Teflaro®. Prior to Forest, Dr. Gergel was a senior leader at SmithKline Beecham where he led the U.S. clinical team responsible for the development and commercial support of Paxil®, which is approved to treat depression, OCD, panic disorder, social phobia and generalized anxiety disorder.

Dr. Gergel received his M.D. from The Royal Free Medical School of The University of London and an MBA from the Wharton School of The University of Pennsylvania.
 Close Bio










          Dorian Hirth        

            Senior Vice President, Human Resources and Facilities Operations          




As Senior Vice President, Human Resources and Facilities Operations, Ms. Hirth is responsible for designing and implementing HR strategies and programs that attract, develop and retain talent for a high-performing workforce. Ms. Hirth's experience spans 19 years at biotechnology companies leading strategic and tactical aspects of human resource functions, including managing issues surrounding mergers and acquisitions. Prior to joining Nektar in 2007, Ms. Hirth headed the human resource programs at Sirna Therapeutics, where she was part of the diligence team during the acquisition process by Merck. She was also part of the team that started SUGEN and transitioned it from start-up through two acquisitions initially by Pharmacia and then by Pfizer Inc. In addition, she served as Vice President, Human Resources and Facilities at Kosan Biosciences and Corgentech/Anesiva. Close Bio










          Maninder Hora, Ph.D.        

            Senior Vice President, Pharmaceutical Development and Manufacturing Operations          




Maninder Hora joined Nektar in August 2010 as Senior Vice President, Pharmaceutical Development and Manufacturing Operations to lead management and oversight of Nektar's CMC, bioanalytical and manufacturing operations worldwide. Dr. Hora has been in the biopharmaceutical industry for 27 years with demonstrated expertise in process, analytical and pharmaceutical sciences, manufacturing and quality functions for biologics, vaccines, small molecules and drug delivery systems. He has led large teams of scientists and engineers to perform early and late stage development as well as lifecycle management CMC activities. He brings to Nektar the experience of registering nine drugs or vaccines products in the United States or Europe. Dr. Hora most recently served as Vice President of Product Operations & Quality at Facet Biotech (a spin-off from PDL BioPharma, now a part of Abbott Laboratories). He joined PDL BioPharma in 2006 as Vice President of Process Development and later took charge of Product Operations & Quality. From 1986 to 2006, Dr. Hora served in various positions of increasing responsibility at Chiron Corporation (now Novartis) with his last position being Vice President of Process and Product Development during the period 2001 to 2006. Dr. Hora also worked at Smith Kline & French (now Glaxo SmithKline) and Ayerst-Wyeth (now Pfizer) prior to joining Chiron.Dr. Hora received his Ph.D. from the Indian Institute of Technology in Bioengineering (Materials) in 1980 and held a Fulbright fellowship at the University of Washington, Seattle. Dr. Hora holds twenty one US Patents and has authored scores of publications and delivered numerous presentations in international forums. He serves as a scientific advisor for Reviva Pharmaceuticals, an emerging research based pharmaceutical company. Close Bio










          Gil M. Labrucherie        

            Senior Vice President and Chief Financial Officer          




Gil M. Labrucherie was appointed Senior Vice President and Chief Financial Officer of the company in June 2016. Mr. Labrucherie has held several senior leadership positions with increasing responsibility at Nektar since 2005, most recently he served as Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Prior to joining Nektar, from October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open, Inc., where he was responsible for global corporate alliances and merger and acquisition activity. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for merger and acquisition transactions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati and Graham & James (DLA Piper Rudnick).Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Close Bio










          John Nicholson        

            Senior Vice President and Chief Operating Officer          




John Nicholson was appointed Senior Vice President and Chief Operating Officer (COO) of the company in June 2016. Mr. Nicholson reports to Nektar's President and Chief Executive Officer, Howard W. Robin. From 2007 to 2016, Mr. Nicholson was Senior Vice President and Chief Financial Officer (CFO). Previously, he was Senior Vice President, Corporate Development and Business Operations at Nektar. Prior to joining Nektar, he served in a number of leadership roles at Bayer Schering Pharma AG, including Vice President, Corporate Development and Treasurer of Schering Berlin Inc., President of Schering Berlin Insurance Company, President of Bayer Pharma Chemicals Inc., and President of Schering Berlin Capital Corporation. Mr. Nicholson also served as Treasurer of Berlex Inc. Close Bio










          Jillian B. Thomsen        

            Senior Vice President, Finance and Chief Accounting Officer          




Jillian B. Thomsen joined Nektar in March 2006 and was appointed Chief Accounting Officer in April 2008. Ms. Thomsen has 20 years of financial reporting and accounting experience. She currently oversees accounting, financial reporting, planning & analysis, Sarbanes-Oxley compliance, treasury and tax.Prior to April 2008, she served as Vice President, Finance and Controller of Nektar. Before joining Nektar, Ms. Thomsen was Deputy Controller of Calpine Corporation from September 2002 to February 2006. From December 1990 to May 2002, Ms. Thomsen performed various roles with Arthur Andersen starting as a staff accountant and concluding as a senior manager. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College. Close Bio










          Carlo J. Di Fonzo, Ph.D.        

            Senior Vice President, Drug Development & Regulatory Affairs          




Carlo J. Di Fonzo leads drug development and regulatory affairs at Nektar with oversight responsibilities for regulatory affairs, GCP/GLP compliance and toxicology. Dr. Di Fonzo's experience includes over 25 years in regulatory affairs and safety roles in the pharmaceutical and biotechnology industry. During his career, Dr. Di Fonzo has been part of several teams that helped bring new medicines to patients, including Lipitor®, Neurontin®, Accupril®, Xigris®, Forteo®, Alimta®, Gemzar®, Zyprexa®, Strattera®, Cialis® and Movantik™. Prior to joining Nektar in 2006, Dr. Di Fonzo led regulatory affairs and quality compliance at Eli Lilly Canada, where he was also responsible for patent-listing strategies and product safety functions. Prior to joining Eli Lilly in November 2000, he worked at Warner-Lambert/Parke-Davis Canada, where he was had oversight of toxicology and safety studies as well as regulatory affairs.
Dr. Di Fonzo received his undergraduate degree in biologic sciences, his master's degree in clinical biochemistry and his Ph.D. in clinical biochemistry and toxicology from the University of Toronto, Canada.
 Close Bio










          Jennifer Ruddock        

            Senior Vice President, Investor Relations & Corporate Affairs          




Jennifer Ruddock heads the investor relations and corporate affairs department at Nektar, which includes public affairs, corporate and employee communications and public relations. Ms. Ruddock's experience spans 20 years in biotechnology, technology and finance. Prior to joining Nektar in 2004, Ms. Ruddock held leadership roles in investor relations, financial communications and corporate marketing at a number of public companies, including Catellus Development Corporation (acquired by ProLogis) and Tumbleweed Communications (acquired by Axway). Prior to that, she worked in the sales and trading department at Montgomery Securities (acquired by Bank of America), a San Francisco-based investment bank which specialized in high technology and healthcare sectors. While at Montgomery, she obtained both her Series 7 and 63 licenses. Ms. Ruddock began her career in medical device sales at Curtin Matheson Scientific, Inc. (acquired by Fisher Scientific). Ms. Ruddock received her undergraduate degree in neuroscience from Colgate University in 1991. Close Bio










          Mary Tagliaferri, M.D.        

            Senior Vice President, Clinical Development          




Mary Tagliaferri provides strategic and operational leadership at Nektar for clinical development, drug safety and risk management, as well as medical affairs and scientific writing. She brings to Nektar over 20 years of experience in pharmaceutical drug development and extensive regulatory expertise in oncology and women's health. Prior to joining Nektar in January 2015, she served as Chief Medical Officer at KangLaiTe USA, a privately-held biotechnology company which develops oncology drug products in multiple solid tumor settings. She also served as a consultant to InterMune, Inc. (acquired by Roche).Prior to that, Dr. Tagliaferri was a co-founder and President and Chief Medical Officer of BioNovo, Inc. At BioNovo, she was responsible for all aspects of the company's clinical drug development strategy including spearheading clinical studies for all drug products, overseeing global regulatory affairs, leading data management and biostatistics, and ensuring the proper conduct of clinical studies. Dr. Tagliaferri received the 2012 State of California Woman of the Year award for her advancements of clinical research in women's health and her mentorship of women in the biotechnology field. Dr. Tagliaferri received her Bachelor of Science degree from Cornell University and her medical degree from the University of California, San Francisco (UCSF). Close Bio










          Jonathan Zalevsky, Ph.D.        

            Senior Vice President, Biology & Preclinical Development          




Jonathan Zalevsky joined Nektar in July 2015 as Vice President of Biology and Preclinical Development to lead biological research and grow the discovery portfolio. Dr. Zalevsky brings over 13 years of experience spanning both large pharmaceutical and small biotechnology companies to Nektar. Prior to joining Nektar, Dr. Zalevsky was the Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and launched products. While at Takeda, Dr. Zalevsky's leadership resulted in 10 new INDs and Phase 1 clinical starts, which included both internally-discovered and in-licensed first-in-class immune-targeting molecules. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, Inc., where he was responsible for the discovery and development of Xencor's first four clinical-stage assets. During that period, he authored numerous high-profile publications on Xencor-discovered drugs and wrote four INDs. Earlier in his career, Dr. Zalevsky worked as a developmental biologist at Stanford University.Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California at San Francisco (UCSF). He received dual bachelor degrees in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. Close Bio










          Kevin Brodbeck, Ph.D.        

            Vice President - CMC Small Molecules (Pharmaceutical Development & Manufacturing)          




Kevin Brodbeck joined Nektar in 2002. As Vice President of Pharmaceutical Development at Nektar, Dr. Brodbeck is responsible drug product development for biologics and small molecules, process chemistry development for small molecule drug substance, and process chemistry development for clinical supply manufacturing. Dr. Brodbeck has over 30 years of pharmaceutical and product development experience in the fields of CNS, pain, and oncology.  Prior to joining Nektar, Dr. Brodbeck headed Formulation and Process Sciences at PowderJect Technologies, and served as the Director of Product Development at ALZA in the Biopharmaceutical Research & Implant Division.  While at ALZA, Dr. Brodbeck developed and commercialized the Viadur (leuprolide 65mg) one-year implant. Dr. Brodbeck was also the lead inventor of number of novel protein delivery technologies for sustained release and improved stability of biopharmaceutical agents.  Dr. Brodbeck received his Ph.D. and M.S. degrees in Chemical Engineering from Stanford and the University of Illinois, and his B.S. degree in Chemical Engineering from the University of California, Berkeley. Dr. Brodbeck is the holder of numerous patents and is published in the field of pharmaceutical formulation, process sciences and drug delivery.  
 Close Bio










          Michael A. Eldon, PhD, FCP        

            Vice President, Clinical Pharmacology          




Dr. Eldon leads Nektar's Clinical Pharmacology department that is responsible for clinical and preclinical pharmacokinetics and ADME, pharmacometrics and systems biology in drug development and discovery. Dr. Eldon, who joined Nektar in 1997, has over 33 years of experience in pharmacokinetics and Clinical Pharmacology in the pharmaceutical industry. Prior to Nektar, Dr. Eldon worked at Parke-Davis Pharmaceutical Research in Ann Arbor, MI where he participated in the development and registration of Lipitor® (atorvastatin), Neurontin® (gabapentin), Rezulin® (troglitazone), Lyrica® (pregabalin), Pro-Air® (procaterol), Lopid® (gemfibrozil), Loestrin® (oral contraceptive), Estrostep® (oral contraceptive), Procanbid® (procainamide extended release), FemPatch® (transdermal estradiol), Cerebyx® (fosphenytoin), Penetrex® (enoxacin), Zagam® (sparfloxacin) and Nitrostat® (nitroglycerin) stabilized tablets. While at Nektar, he has participated in the development and registration of Movantik™(naloxegol), and the preclinical and clinical development of all other Nektar proprietary products including NKTR-181, NKTR-214 and NKTR-102.
Dr. Eldon received his undergraduate degree in pharmacy and PhD in Biopharmaceutics and Pharmacokinetics from the University of Cincinnati. He is a member of several pharmaceutical societies, has authored over 100 scientific articles and presentations, and is a Fellow of the American College of Clinical Pharmacology.
 Close Bio










          Chulani Karunatilake, Ph.D.        

            Vice President-CMC Biologics (Pharmaceutical Development & Manufacturing)          




Chulani Karunatilake joined Nektar in 2011 as Vice President, Pharmaceutical Development & Manufacturing. In this role, Dr. Karunatilake is responsible for Biologics CMC and has global responsibilities for Analytical, Bioanalytical and Quality Control functions.  Dr. Karunatilake has over 20 years of experience in the biopharmaceutical industry having contributed to several successful biotechnology drug development and registration efforts at Amgen, Chiron/Novartis, and Genentech.  Prior to Nektar, Dr. Karunatilake was Director, Process Development at Amgen-Fremont where he was responsible for the Analytical and Purification Development departments and led the Quality by Design (QbD) task force in the FDA pilot program.  Prior to Amgen, Dr. Karunatilake was Senior Director responsible for Analytical Development and Quality Control functions at Chiron/Novartis. Prior to Chiron-Novartis he was at Genentech where he held management roles of increasing responsibility in Analytical Technologies and Quality Control areas.  
Dr. Karunatilake received his Ph.D. in Biochemistry/Chemistry from University of Illinois.  He received his B.Sc. (Honors) degree in Chemistry from University of Colombo, Sri Lanka.   Close Bio










          Henk Kocken, Ph.D.        

            Vice President, Quality Assurance          




Henk Kocken joined Nektar in October 2015 as Vice President, Quality Assurance. Dr. Kocken brings over 20 years of experience in the management of quality systems and quality assurance in the biopharmaceutical industry to Nektar. Prior to joining Nektar, Dr. Kocken served as the VP of Regulatory Affairs and Quality for Alvine Pharmaceuticals. Prior to Alvine, Dr. Kocken was VP of Quality Systems at VaxGen, where he led the Quality Unit responsible for developing compliance, quality assurance, and quality control systems for the development, manufacture and control of anthrax and smallpox vaccines. Before VaxGen, Dr. Kocken served in various senior quality assurance and systems roles at CoTherix, InterMune, Fibrogen, Bio-Rad Laboratories and Clontech Laboratories.Prior to his career in industry, Dr. Kocken was Assistant Professor of Molecular Biology at the Eindhoven University of Technology in the Netherlands. He received his Ph.D. in Chemical Technology from Eindhoven University of Technology and his M.S. in Molecular Biology from Nijmengen University in the Netherlands. Close Bio










          Mark A. Wilson        

            Vice President and General Counsel          




Mark A. Wilson has been our Vice President and General Counsel since July 2016. Mr. Wilson has over 20 years in the legal field, with a particular emphasis on intellectual property. Prior to serving as Nektar’s General Counsel, Mr. Wilson led Nektar’s intellectual property department with oversight for the company's extensive patent portfolio, including the preparation and prosecution of patent applications. Prior to joining Nektar in 2002, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he successfully represented both start-up and Fortune 500 companies. Mr. Wilson received his J.D. from Seton Hall University, School of Law, and his B.S. in pharmacy from Rutgers University, College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office. Close Bio










          Sunny Xie        

            Vice President, Biometrics and R&D Systems          




Sunny Xie leads Biometrics and R&D Systems at Nektar with oversight of biostatistics and statistical programming for clinical development. Mr. Xie brings 20 years of statistics and programming experience in both biotech and large pharmaceutical companies to Nektar. Prior to joining Nektar in 2015, Mr. Xie was Senior Director, Statistical Programming at Gilead Sciences, Inc. While at Gilead, Mr. Xie led statistical programming group that supported all therapeutic areas including HIV, Liver Disease, Oncology, Inflammation & Respiratory and Cardiovascular. Prior to Gilead, Mr. Xie worked at Shire Pharmaceuticals overseeing process improvement, clinical applications, and support and training in Clinical Development, Operations and Biometrics. Before Shire, he spent more than 5 years at Forest Laboratories as the Executive Director of Statistical Programming. Earlier in his career, he held various roles in the Biometrics groups at Eli Lilly & Company and at Pharmacia (now Pfizer). Mr. Xie received his Masters of Science degree in Statistics from Sam Houston State University in Huntsville, Texas and his Bachelor of Science degree in Applied Mathematics and Application Software Design from Shandong University in China. Close Bio






Our StoryOur LeadershipOur Board of DirectorsOur PartnersLocationsContact






      Read the Latest News    






      Join Nektar and Make a Difference    














OKAY
GO BACK















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft













Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          











Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          











Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          


















Amazon.com: Amazon Music Unlimited








































Interesting Finds Updated Daily










Amazon




    Try Prime
  


















Digital Music



All Departments
Alexa Skills
Amazon Devices
Amazon Video
Amazon Warehouse Deals
Appliances
Apps & Games
Arts, Crafts & Sewing
Automotive Parts & Accessories
Baby
Beauty & Personal Care
Books
CDs & Vinyl
Cell Phones & Accessories
Clothing, Shoes & Jewelry
   Women
   Men
   Girls
   Boys
   Baby
Collectibles & Fine Art
Computers
Courses
Credit and Payment Cards
Digital Music
Electronics
Gift Cards
Grocery & Gourmet Food
Handmade
Health, Household & Baby Care
Home & Business Services
Home & Kitchen
Industrial & Scientific
Kindle Store
Luggage & Travel Gear
Luxury Beauty
Magazine Subscriptions
Movies & TV
Musical Instruments
Office Products
Patio, Lawn & Garden
Pet Supplies
Prime Exclusive
Prime Pantry
Software
Sports & Outdoors
Tools & Home Improvement
Toys & Games
Vehicles
Video Games
Wine





Go

















Departments









EN

 
      




Hello. Sign inAccount & ListsSign inAccount & ListsOrdersTry PrimeCart0






Your Amazon.comToday's DealsGift Cards & RegistrySellHelpDisability Customer Support 






 Amazon Music Unlimited Prime Music CDs & Vinyl Download Store         Open Web Player MP3 cart Settings













































































































$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          




$7.99/mo for Prime members




Non-Prime price: $9.99/month



Change or cancel anytime




            Start your 30-day free trial
          
















Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.




Any song, anywhere




Tens of millions of songs with new releases from today's most popular artists. Listen ad-free with unlimited skips. Download for offline listening.
















Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).




Already using Prime Music?




Upgrade to Amazon Music Unlimited now to unlock tens of millions of songs, including the hottest new releases. Only $7.99/month or $79/year (12 months for the price of 10).
















Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More




Better with Echo - Just ask




Play your favorite music with innovative Alexa voice controls, exclusive to Amazon Music.




Want Amazon Music Unlimited just on your Echo? Learn More


























Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          




Choose the right Amazon Music plan for you




Learn More




Learn More




Learn More




Questions? See our FAQ.





            Start free trial
          

















There's a problem loading this menu right now.
Learn more about Amazon Prime.






 Get fast, free shipping with Amazon Prime 
 Prime members enjoy FREE Two-Day Shipping and exclusive access to music, movies, TV shows, original audio series, and Kindle books. 

      >
      Get started

















v



























Robot Check













Enter the characters you see below
Sorry, we just need to make sure you're not a robot. For best results, please make sure your browser is accepting cookies.










Type the characters you see in this image:








Try different image











Continue shopping











Conditions of Use




Privacy Policy


          © 1996-2014, Amazon.com, Inc. or its affiliates
          







